Following the launch of the #WhatsYourPlan campaign in November 2021, ADI examines the campaign’s successes in its first year.
Alzheimer and dementia associations in the Caribbean are calling for National Dementia Plans to be created and implemented through the #WhatsYourPlan campaign.
Professor Huali Wang of Alzheimer's Disease Chinese (ADC) explains how China has addressed the specific challenges of people living with dementia during COVID-19.
ADI's Global Perspective for February 2020 now available.
Roche announces end of DIAN-TU-001 study after it failed to meets its primary endpoint in people who are affected by early onset Autosomal dominant Alzheimer’s disease.
hinese Pharmaceutical Company Green Valley announces their drug Oligomannate (GV-971) has been granted conditional approval for the treatment of "mild to moderate Alzheimer's disease".
Biogen and Eisai have announced they will file for market approval for an investigational treatment for early Alzheimer’s disease.
Ahead of the G20 Health Ministers Meeting in Okayama, ADI’s Chief Executive Paola Barbarino and Noriyo Washizu of Alzheimer's Association Japan (AAJ) continue to work on progress made earlier in the year at the Osaka Summit.
Ahead of the G20 Health Ministers Meeting in Okayama, ADI Chief Executive Paola was interviewed by one of Japan's largest newspaper.
The Spanish Ministry of Health, Consumption and Social Welfare has announced that they have adopted a national dementia plan.